HeartSciences Inc. filings document the company’s AI-enabled ECG business, public securities and governance as a Texas corporation listed on Nasdaq. The records identify common stock under HSCS and warrants under HSCSW, and include emerging growth company disclosures.
Recent filings include Form 8-K reports for quarterly operating results and business updates, material definitive agreements covering debt and lending arrangements, and governance matters such as director and officer indemnification and executive or board changes. Proxy materials describe annual meeting proposals including director elections, equity incentive plan shares, officer exculpation under Texas law and auditor ratification.
HeartSciences Inc. reported voting results from its Annual Meeting of Stockholders. Shareholders representing 1,973,863 shares, or 57% of the 3,477,698 shares entitled to vote as of March 6, 2026, were present, establishing a quorum.
Shareholders elected Andrew Simpson as a Class III director, approved an increase in shares reserved under the 2023 Equity Incentive Plan to 1,250,000 shares plus a formula-based annual add-on, and ratified Haskell & White LLP as independent auditor for the fiscal year ending April 30, 2026. A charter amendment to add limited officer exculpation did not obtain the required majority, while an adjournment proposal to allow additional proxy solicitation was approved.
HeartSciences Inc. reported the death of Mark Hilz, its Chief Operating Officer, Corporate Secretary and a board member, who passed away on April 1, 2026 at age 67 after a period of illness. He had served on the Board since 2013 and as COO and Corporate Secretary since March 2022.
The company states it does not expect to hire a new Chief Operating Officer in the foreseeable future, noting that its MyoVista Insights™ software platform has been launched and the MyoVista® wavECG™ device has been submitted to the U.S. Food and Drug Administration for 510(k) premarket clearance. HeartSciences does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform as a result of his passing.
HeartSciences Inc. is calling a virtual annual shareholder meeting on April 30, 2026 to vote on several governance and compensation matters. Shareholders of common stock and Series C preferred stock as of March 6, 2026 may participate and vote.
Key items include re-electing Andrew Simpson as the Class III director, and expanding the 2023 Equity Incentive Plan to reserve up to 1,250,000 shares of common stock plus an automatic “evergreen” increase. Shareholders will also vote on adding officer exculpation language to the certificate of formation, within limits allowed by recent Texas law.
Other proposals ask shareholders to ratify Haskell & White LLP as auditor for the year ending April 30, 2026 and to authorize potential adjournment of the meeting if additional proxy solicitation is needed. The proxy describes board structure, committee independence, director pay and current ownership, with three of five directors classified as independent.
HeartSciences Inc. reported fiscal third-quarter 2026 results and shared a business update. The healthcare IT company is focused on commercializing its MyoVista Insights ECG platform and has submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, an important regulatory milestone.
The company reported no meaningful revenue for the quarter as it continues investing in commercialization. As of January 31, 2026, it held approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity. Full financial details are available in its Form 10-Q for the same period.
HeartSciences Inc. reported another loss-making quarter for the period ended January 31, 2026, with a nine‑month net loss of $6.4 million and minimal revenue of $4,319. Operating expenses were driven by research and development and general and administrative costs, while interest expense added further pressure.
Cash and cash equivalents were $3.4 million against $7.6 million in total assets and $4.9 million in total liabilities, leaving stockholders’ equity at $2.7 million. The company discloses substantial doubt about its ability to continue as a going concern and is relying on external financing, including a $3.6 million Streeterville note and a Series D preferred stock offering that raised about $6.7 million.
HeartSciences Inc. is soliciting shareholder votes at a virtual Annual Meeting to be held via webcast on April 30, 2026, with a record date of March 6, 2026.
The Board asks shareholders to (1) elect directors, (2) approve an increase to the 2023 Equity Incentive Plan to 1,250,000 shares plus the Evergreen Shares, (3) approve an amendment to the Certificate of Formation to permit officer exculpation as allowed by Texas law, (4) ratify the independent auditor, and (5) approve adjournment authority if votes are insufficient. Voting instructions and proxy access details are included in the Proxy Statement.
HeartSciences Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, issuing an unsecured promissory note for $3,605,000, which includes a $600,000 original issue discount and $5,000 of transaction expenses, for gross cash proceeds of $3,000,000. The Note carries 12% annual interest, matures 18 months after issuance, and allows Streeterville, starting six months after issuance, to require monthly redemptions of up to $405,000. If the outstanding balance has not been reduced by at least $1,250,000 by the 12‑month anniversary, the outstanding balance at that time automatically increases by 5%. The Note and related agreement include customary covenants, events of default, potential default interest up to 18% (or the legal maximum), and indemnification of Streeterville, and were issued as an unregistered private placement under Section 4(a)(2) and Rule 506.
HeartSciences Inc. director David R. Wells reported a grant of 15,000 Restricted Stock Units (RSUs) on 01/12/2026. The RSUs were granted under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU convertible into one share of common stock.
Vesting is subject to several conditions. Shareholders must first approve plan changes that contemplate these RSU awards. After that, one-half of the RSUs vest on the one-year anniversary of the grant date, and one-eighth vests on each quarterly anniversary thereafter, so all units vest over two years if Wells continues serving on the board. Separately, 100% of the RSUs vest early if there is a Change of Control or if the company records at least $250,000 of revenue in any fiscal quarter after the grant date.
HeartSciences Inc. granted director Bruce Bent 15,000 restricted stock units (RSUs) on January 12, 2026. The RSUs were issued under the company’s 2023 Equity Incentive Plan at a price of $0 per unit, with each vested RSU delivering one share of common stock.
The award vests only if shareholders approve changes to the equity plan that contemplate these RSUs. If that condition is met, half of the RSUs vest one year after the grant date, and the remaining units vest in equal quarterly installments so that all RSUs are fully vested two years after the grant date, as long as Bent continues serving on the board.
The filing also notes that 100% of the RSUs will vest early if there is a Change of Control as defined in the plan, or if HeartSciences generates $250,000 or more of revenue in any fiscal quarter ending after the grant date.
HeartSciences Inc. approved a form of indemnification agreement on December 15, 2025 for each of its directors and executive officers. The agreement states that the company will indemnify these individuals and advance their expenses to the fullest extent permitted under Texas law and the company’s Certificate of Formation.
The arrangement also provides for continued coverage of each director and executive officer under the company’s directors’ and officers’ insurance policies. The form of indemnification agreement is filed as Exhibit 10.1.